PharmaShots | Incisive News in 3 Shots

Subscribe Now

Advanced Melanoma

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

June 18, 2021

Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

August 25, 2020

Roche's Tecentriq + Cotellic and Zelboraf Receives the US FDA's Approval for Patients with Advanced Melanoma

Roche's Tecentriq + Cotellic and Zelboraf Receives the US FDA's Approval for Patients with Advanced Melanoma

July 31, 2020

Nektar and BMS Receive the US FDA's Breakthrough Designation for Bempegaldesleukin (NKTR-214) + Opdivo (nivolumab) to Treat Advanced Melanoma

Nektar and BMS Receive the US FDA's Breakthrough Designation for Bempegaldesleukin (NKTR-214) + Opdivo (nivolumab) to Treat Advanc...

August 2, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us